Your browser doesn't support javascript.
loading
Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer.
Lin, Hongmei; Chen, Yuhchyau; Shi, Anhui; Pandya, Kishan J; Yu, Rong; Yuan, Yannan; Li, Jiancheng; Li, Hang; Wang, Yingjie; Xia, Tingyi; Feng, Linchun; Ma, Huimin; Geng, Jianhao; Zhu, Guangying.
Afiliación
  • Lin H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China; Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, China.
  • Chen Y; Department of Radiation Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center , Rochester, NY , USA.
  • Shi A; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute , Beijing , China.
  • Pandya KJ; Division of Hematology and Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center , Rochester, NY , USA.
  • Yu R; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute , Beijing , China.
  • Yuan Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute , Beijing , China.
  • Li J; Department of Radiation Oncology, Fujian Province Cancer Hospital , Fuzhou , China.
  • Li H; Department of Radiation Oncology, Guizhou Province People's Hospital , Guiyang , China.
  • Wang Y; Department of Radiation Oncology, Air Force General Hospital, PLA , Beijing , China.
  • Xia T; Department of Radiation Oncology, Air Force General Hospital, PLA , Beijing , China.
  • Feng L; Department of Radiation Oncology, Chinese PLA General Hospital , Beijing , China.
  • Ma H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute , Beijing , China.
  • Geng J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute , Beijing , China.
  • Zhu G; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China; Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, China.
Front Oncol ; 6: 260, 2016.
Article en En | MEDLINE | ID: mdl-28066716
INTRODUCTION: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) but is associated with poor chest tumor control. Here, we report results of a randomized phase 3 study comparing two CCRT regimens in improving chest tumor control by low-dose paclitaxel chemoradiation for LA-NSCLC. METHODS: Due to the logistics of local referral pattern, the study was designed to enroll patients with stage III LA-NSCLC who had completed 2-4 cycles of full-dose chemotherapy. One hundred thirty four were randomized to either Arm 1 [paclitaxel at 15 mg/m2, three times per week (Monday, Wednesday, and Friday) for 6 weeks, n = 74] or Arm 2 (weekly paclitaxel at 45 mg/m2 for 6 weeks, n = 60). Chest radiotherapy was 60-70 Gy in standard fractionation. Response rate was the primary endpoint, with recurrence-free survival (RFS) as the secondary endpoint. RESULTS: From March 2006 to February 2013, 71 patients completed Arm 1 treatment and 59 completed Arm 2 treatment. The response rate for Arm 1 was significantly higher (83.1%) than Arm 2 (54.2%) (p=0.001). RFS was superior in Arm 1: median 14.6 vs. 9.4 months, p = 0.005, Hazard ratio (HR) 1.87 [95% confidence interval (CI) 1.20, 2.90]. Overall survival was not significantly different: median 32.6 months in Arm 1 vs. 31.3 months in Arm 2, p = 0.91, HR 0.97 (95% CI 0.55, 1.70). Toxicity was significantly lower in Arm 1 for Grade 3 and 4 leukopenia/neutropenia (p < 0.001). CONCLUSION: Pulsed low-dose paclitaxel CCRT resulted in significantly better RFS and tumor response rate, and less hematologic toxicities than weekly CCRT for LA-NSCLC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Oncol Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Oncol Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza